Clinical trials: Endometriosis
Endometriosis, Pain
Endocare® (Single Care) in Pain-related Endometriosis
Endocare® treatment is a stand-alone software medical device, which is composed of a mobile application and an accessory VR headset, intended to mitigate the pain for patients prone to endometriosis.
- Trial name
- NCT04650516
- Testing
- Virtual reality, Digital control
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Lucine
Prostate Cancer, Endometriosis
A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects
This is a nonrandomized, open-label, fixed-sequence, 2-arm study designed to assess the effect of multiple doses of fluconazole or atorvastatin on the single-dose pharmacokinetics of TAK-385 in healthy adult subjects.
- Trial name
- NCT02093390
- Testing
- TAK-385, Fluconazole, Atorvastatin
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Endometriosis
Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis
This will be a randomized, double-blind, placebo-controlled, proof-of-mechanism phase 2 trial investigating the effect of quinagolide extended-release vaginal ring on reduction of lesions assessed by high-resolution magnetic…
- Trial name
- QLARITY (NCT03749109)
- Testing
- Quinagolide 1080 µg
- Where
- 11 sites in Denmark, Germany and 2 more
- Volunteers
- 67 people
- Sponsor
- Ferring Pharmaceuticals
Endometriosis
A Study of Pharmacokinetic/Pharmacodynamic Profile of Orally Administered Leuprolide in Healthy Female Volunteers
This Phase 2a, pharmacokinetic/pharmacodynamic study will determine the safety and provide evaluation of the PK/PD metrics of three different oral doses selected upon the results of the study LOPDT-PH1-01 - 4 mg oral tablets…
- Trial name
- NCT02807363
- Testing
- Leuprolide Oral Tablet 4-mg QD, Leuprolide Oral Tablet 4-mg BID, Leuprolide Depot
- Where
- Canada
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Enteris BioPharma Inc.
Cancer, Pregnancy Related
Distribution of Biospecimens From Biorepositories/Biobanks for Research Use
This protocol seeks to assist biorepositories/biobanks in distributing their stored specimens and data to researchers that will actually utilize them to advance medicine and technology.
- Conditions
- Cancer, Pregnancy Related, Gastro-Intestinal Disorder, Cardio-Respiratory Distress
- Trial name
- NCT03884400
- Testing
- Specimens obtained from surgical, phlebotomy or other non-invasive procedure
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- iSpecimen Inc
Endometriosis
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
The primary objective of this study is to assess the efficacy and safety of a range of oral doses of OBE2109 versus placebo, in reducing endometriosis associated pain.
- Trial name
- EDELWEISS (NCT02778399)
- Testing
- OBE2109
- Where
- 86 sites in United States, Poland and 2 more
- Volunteers
- 328 people
- Sponsor
- ObsEva SA
Endometriosis, Diagnosis
Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers
This study is testing a way to diagnose endometriosis using a uterine tissue biopsy (similar to a pap smear) as opposed to undergoing laparoscopy surgery.
- Trial name
- NCT05698212
- Testing
- MetriDx
- Where
- 3 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Hera Biotech, Inc.
Patient With a Prescribed Endotest, Endometriosis (Diagnosis)
Impact of Endotest on Patients' Quality of Life: a Cohort Study
Ziwig Endotest® ('Endotest') is marketed in several countries, including Switzerland, which was the first country to make it available in 2022.
- Trial name
- ENDOLIFE (NCT07560852)
- Testing
- Questionnaire
- Where
- 7 sites in France
- Volunteers
- 20,000 people
- Sponsor
- ZIWIG
Endometriosis
Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis
This study is designed to evaluate the safety and beneficial effects of elagolix (NBI-56418) compared to placebo and leuprorelin (an approved endometriosis therapy) over a three month period followed by an additional three months…
- Trial name
- NCT00797225
- Testing
- Leuprorelin Acetate Depot, Elagolix
- Volunteers
- 174 people
- Sponsor
- AbbVie
Endometriosis
Regulatory Post Marketing Surveillance Study in Korea
The objective of the study is to investigate and collect post marketing data on the safety and efficacy of Visanne at follow-up visit after about 6 months of treatment and - for a subset of patients - at optional long-term…
- Trial name
- NCT01788722
- Testing
- Dienogest (Visanne, BAY86-5258)
- Where
- South Korea
- Volunteers
- 3,223 people
- Sponsor
- Bayer
Endometriosis
Validation Study for Endometriosis PRO
Assess the psychometric properties of the Endometriosis Symptom Diary (ESD) and the Endometriosis Impact Scale (EIS) and provide evidence whether the PRO measures are reliable, valid and able to detect changes over time in…
- Trial name
- VALEPRO (NCT01643122)
- Testing
- No drug
- Where
- 21 sites in United States, Germany
- Volunteers
- 275 people
- Sponsor
- Bayer
Endometriosis, Pelvic Pain
Hyivy Device as Non-hormonal Therapy in Endometriosis
This study seeks to address accessible management of endometriosis-associated chronic pelvic pain by evaluating a novel device used in the home.
- Trial name
- NCT05643131
- Testing
- Hyivy Intravaginal Device
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Hyivy Health Inc
Endometriosis
A Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy, Safety and Duration of Effect of a Single Administration of Various Doses of Cetrorelix SR in Subjects With Histologically Confirmed Endometriosis
Identify effective doses of cetrorelix SR in the treatment of symptoms of endometriosis, describe dose effect relationship and duration of symptom relief
- Trial name
- NCT00244452
- Testing
- Cetrorelix
- Where
- 57 sites in Australia, Belgium and 6 more
- Sponsor
- Solvay Pharmaceuticals
Endometriosis
Multicenter Study for Diagnostic Validation of a Laboratory Test for the Diagnosis of Endometriosis
Endometriosis affects at least 1 in 10 women worldwide and is associated with a diagnostic delay of 5-10 years. Currently, definitive diagnosis requires invasive laparoscopy, which is costly and burdensome for patients.
- Trial name
- NCT07553676
- Where
- 8 sites in Austria, Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Diamens FlexCo
Folliculogenesis
An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females
This is an open-label Phase 1 study in healthy premenopausal females evaluating the effects of different dosing regimens of elagolix on ovarian activity, ovulation, and ovarian reserve and to assess the effect of elagolix on…
- Trial name
- NCT01403038
- Testing
- Elagolix
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- AbbVie (prior sponsor, Abbott)
Patients Who Were Scheduled for General and Gynecological Laparoscopic Procedures
Evaluation of the Follow Me Mode of the AutoLap System - A Feasibility Study
The main objectives of this study are to evaluate the performance and ease of use of the Follow me mode of the AutoLap system during general and gynecological laparoscopic procedures.
- Trial name
- NCT02326870
- Testing
- AutoLap
- Where
- 4 sites in Israel, Netherlands
- Volunteers
- 33 people
- Sponsor
- M.S.T. Medical Surgery Technology LTD.
Endometriosis
Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain
The primary objective of this extension study is to assess the maintenance of efficacy of linzagolix administered orally once daily for up to an additional 6 months (for up to 12 months of treatment in total) in women who have…
- Trial name
- EDELWEISS 5 (NCT04372121)
- Testing
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg)
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Endometriosis
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of SKI2670
In this Phase I study, the primary objective is to investigate the safety and tolerability of SKI2670 after oral administration in healthy female subjects.
- Trial name
- NCT02202408
- Testing
- SKI2670
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Endometriosis
A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain
The primary objective of this study is to demonstrate the efficacy and safety of linzagolix administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in combination with add-back hormone replacement…
- Trial name
- NCT03986944
- Testing
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg)
- Where
- 112 sites in United States, Canada and 1 more
- Volunteers
- 85 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Endometriosis
A Randomized, Placebo-controlled, Double-blind Study of KLH-2109 in Patients With Endometriosis (2)
The purpose of this study is to evaluate the efficacy and safety of KLH-2109 in patients with endometriosis.
- Trial name
- NCT01533532
- Testing
- KLH-2109
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.